<DOC>
	<DOCNO>NCT01485549</DOCNO>
	<brief_summary>The main objective determine one hand whether oligomeric alpha-synuclein level increase MSA patient compare control hand whether good agreement cerebrospinal fluid ( CSF ) plasma level .</brief_summary>
	<brief_title>Oligomeric Alpha-synuclein Multiple System Atrophy</brief_title>
	<detailed_description>Multiple system atrophy ( MSA ) rare neurodegenerative disorder characterize variable combination parkinsonism , cerebellar dysfunction , autonomic failure , additional sign . No effective treatment available . Together PD Lewy body dementia , MSA belong group neurodegenerative disorder , alpha-synucleinopathies , characterize abnormal accumulation alpha-synuclein . The development biological marker diagnosis prognosis MSA remain unmet need . Such biological marker crucial future disease-modification neuroprotection trial . Alpha-synuclein high potential biomarker development since constitutes pathological hallmark feature MSA . The oligomeric alpha-synuclein seem particularly involve abnormal protein aggregation alpha-synucleinopathies . The study compare alpha-synuclein level CSF plasma patient suffer AMS control patient require spinal tap without affected neurodegenerative disorder . The MSA patient control receive CSF blood sample one study visit .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<criteria>MSA patient : Patients suffer `` probable '' MSA accord clinical consensus criterion ( Gilman et al , 2008 ) Age ≥ 30 Written informed consent Patient cover French health insurance system Controls : Patients suffer neurodegenerative disorder require spinal tap Age ≥ 30 Written informed consent Patient cover French health insurance system MSA patient : UMSARS IV score &gt; 4 point Patient coagulopathy , define abnormal activate partial thromboplastin time INR Patient thrombocytopenia Patient tutelage Patient unable give consent Controls : Patient coagulopathy , define abnormal activate partial thromboplastin time INR Patient thrombocytopenia Patient tutelage Patient unable give consent</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple system atrophy ( MSA )</keyword>
	<keyword>alpha-synucleinopathies</keyword>
	<keyword>biological marker</keyword>
	<keyword>cerebrospinal fluid</keyword>
	<keyword>plasma</keyword>
</DOC>